Literature DB >> 7506010

Palliative operations for pancreatic cancer in the hospitals of the U.S. Department of Veterans Affairs from 1987 to 1991.

T J Neuberger1, T P Wade, T J Swope, K S Virgo, F E Johnson.   

Abstract

A total of 1,180 patients underwent palliative surgery for pancreatic cancer in the 158 hospitals of the U.S. Department of Veterans Affairs from 1987 to 1991. Using computerized data files, we analyzed these procedures according to type of procedure (gastric bypass only [GO], biliary bypass only [BO], or combined biliary and gastric bypass [BG]), survival, reoperation and complication rates, patient age, and operative (30-day) mortality. Survival after GO (208 days) was significantly shorter than after BO or BG (279 days and 259 days, respectively; p < or = 0.05 by analysis of variance). The reoperation rate after BO (12%) was higher than after BG (5%; p < or = 0.001 by chi 2 analysis) and was due to the higher incidence of reoperative gastric bypass in the BO group. Complication rates were similar after all bypass types. Reoperations had a 25% 30-day mortality. The 32 gastric bypasses performed after an initial BO were done at a mean of 193 days after the original BO bypass, whereas other reoperations were undertaken at a mean of 73 days after the first operation. This first national study of palliative operations for pancreatic cancer supports combined biliary/gastric bypass as the initial procedure, thus minimizing reoperations and their attendant morbidity.

Entities:  

Mesh:

Year:  1993        PMID: 7506010     DOI: 10.1016/s0002-9610(05)80669-5

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  10 in total

1.  Palliative surgery for unresectable pancreatic and periampullary cancer: a reappraisal.

Authors:  Mickael Lesurtel; Nidal Dehni; Emmanuel Tiret; Rolland Parc; François Paye
Journal:  J Gastrointest Surg       Date:  2006-02       Impact factor: 3.452

Review 2.  [Palliative bypass surgery].

Authors:  A Wojtyczka; T Moesta; C Kuntz; T Lehnert
Journal:  Chirurg       Date:  2006-03       Impact factor: 0.955

Review 3.  Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.

Authors:  Chakshu Sharma; Karim M Eltawil; Paul D Renfrew; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

Review 4.  Biliary and gastric bypass or stenting in nonresectable periampullary cancer: analysis on the basis of controlled trials.

Authors:  A Schwarz; H G Beger
Journal:  Int J Pancreatol       Date:  2000-02

5.  Surgical bypass vs. endoscopic stenting for pancreatic ductal adenocarcinoma.

Authors:  Edwina N Scott; Giuseppe Garcea; Helena Doucas; Will P Steward; Ashley R Dennison; David P Berry
Journal:  HPB (Oxford)       Date:  2009-03       Impact factor: 3.647

6.  Stomach-preserving gastric bypass for unresectable pancreatic cancer.

Authors:  M Konishi; M Ryu; T Kinoshita; N Kawano; H Tanizaki; A Cho
Journal:  Surg Today       Date:  1997       Impact factor: 2.540

7.  Palliative surgical bypass for pancreatic and peri-ampullary cancers.

Authors:  Samrat Mukherjee; Hemant M Kocher; Robert R Hutchins; Satyajit Bhattacharya; Ajit T Abraham
Journal:  J Gastrointest Cancer       Date:  2007

8.  Pain management of patients with unresectable peripancreatic carcinoma.

Authors:  Rutger C I van Geenen; Claudia M G Keyzer-Dekker; Geertjan van Tienhoven; Huug Obertop; Dirk J Gouma
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

9.  Hepaticocholecystoduodenostomy compared with Roux-en-y choledochojejunostomy for decompression of the biliary tract.

Authors:  Omar Shah; Parveen Shah; Showkat Zargar
Journal:  Ann Saudi Med       Date:  2009 Sep-Oct       Impact factor: 1.526

10.  Palliative interventional and surgical therapy for unresectable pancreatic cancer.

Authors:  Volker Assfalg; Norbert Hüser; Christoph Michalski; Sonja Gillen; Jorg Kleeff; Helmut Friess
Journal:  Cancers (Basel)       Date:  2011-02-14       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.